Teva/Alvotech follow Amgen in launching biosimilar for J&J's Stelara
Source: SeekingAlpha
2025-02-21 07:06:07 ET
More on Alvotech, Amgen, etc.
- Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)
- AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
- Johnson & Johnson: Rich History Of Excellence Poised To Endure
- Corcept accused in California of stifling Teva’s generic launch
- J&J bankruptcy hearing for talc cases kicks off in Texas
Read the full article on Seeking Alpha
For further details see:
Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara
Alvotech
NASDAQ: ALVO
ALVO Trading
-6.23% G/L:
$3.01 Last:
679,105 Volume:
$3.23 Open:
ALVO Latest News
May 11, 2026 04:30:00 am
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
ALVO Stock Data
$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg
